Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | EVP R&D, Chief Medical Officer | September 01, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date September 01, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 65,389 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 5,000 · Balance 74,389 F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Row 2 · 2026-09-01 · Sale · Disposed 9,000 · Balance 65,389 F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.59 · Expires 2032-02-18 | Direct | 61,276 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Disposed 5,000 · Balance 61,276 F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4: These options are fully vested in accordance with their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
F4: These options are fully vested in accordance with their terms.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBIREO PHARMA, INC.
Report date March 02, 2023 · Filed March 02, 2023
Section 16 reporting ended · disclosed 2023-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-02 · Disposition to issuer · Disposed 10,495 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share"). F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F5: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share").
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time").
F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027;
F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect.
F5: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 1, 2026 23:08 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $24.59 | $0.00 |
DisclosureSEC source: 0001520262-26-000118 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,276 Underlying: Ordinary Shares · 5,000 shares Expires 2032-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 23:08 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 9,000 | $46.99 | $422,874.00 |
DisclosureSEC source: 0001520262-26-000118 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,389 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 23:08 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $24.59 | $122,950.00 |
DisclosureSEC source: 0001520262-26-000118 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 23:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,896 | $0.00 Strike: $24.59 | $0.00 |
DisclosureSEC source: 0001520262-26-000110 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,276 Underlying: Ordinary Shares · 4,896 shares Expires 2032-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 23:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 104 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-26-000110 · form4.xml · derivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,252 Underlying: Ordinary Shares · 104 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 23:12 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 9,000 | $48.58 | $437,220.00 |
DisclosureSEC source: 0001520262-26-000110 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,389 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 23:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 4,896 | $24.59 | $120,392.64 |
DisclosureSEC source: 0001520262-26-000110 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 23:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 104 | $19.34 | $2,011.36 |
DisclosureSEC source: 0001520262-26-000110 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 22:29 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-26-000103 · form4.xml · derivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,356 Underlying: Ordinary Shares · 5,000 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F5 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 22:29 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 700 | $52.13 | $36,491.98 |
DisclosureSEC source: 0001520262-26-000103 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,389 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.10 to $52.17. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 22:29 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 8,300 | $51.46 | $427,128.79 |
DisclosureSEC source: 0001520262-26-000103 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,089 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.06 to $52.04. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 22:29 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $19.34 | $96,700.00 |
DisclosureSEC source: 0001520262-26-000103 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 23:26 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-26-000097 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,356 Underlying: Ordinary Shares · 5,000 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 23:26 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 9,000 | $41.67 | $375,043.50 |
DisclosureSEC source: 0001520262-26-000097 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,389 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.37 to $42.19. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 23:26 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $19.34 | $96,700.00 |
DisclosureSEC source: 0001520262-26-000097 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:05 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-26-000072 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,356 Underlying: Ordinary Shares · 5,000 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:05 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 9,000 | $33.40 | $300,559.50 |
DisclosureSEC source: 0001520262-26-000072 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,389 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.21 to $33.49. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:05 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $19.34 | $96,700.00 |
DisclosureSEC source: 0001520262-26-000072 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 22:58 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-26-000065 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,356 Underlying: Ordinary Shares · 5,000 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 22:58 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 9,000 | $35.51 | $319,604.40 |
DisclosureSEC source: 0001520262-26-000065 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,389 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.50 to $35.62. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 22:58 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $19.34 | $96,700.00 |
DisclosureSEC source: 0001520262-26-000065 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:16 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 38,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-26-000058 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,568 Underlying: Ordinary Shares · 38,568 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 3/2/2027. F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 3/2/2027. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:16 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 83,037 | $0.00 Strike: $30.25 | $0.00 |
DisclosureSEC source: 0001520262-26-000058 · form4.xml · derivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,037 Underlying: Ordinary Shares · 83,037 shares Expires 2036-03-02 F5 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 3/2/2027. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:16 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-26-000058 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,356 Underlying: Ordinary Shares · 5,000 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:16 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 9,000 | $29.72 | $267,485.40 |
DisclosureSEC source: 0001520262-26-000058 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,389 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.29 to $30.13. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:16 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $19.34 | $96,700.00 |
DisclosureSEC source: 0001520262-26-000058 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:38 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000046 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,732 Underlying: Ordinary Shares · 6,866 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/26/2025. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/26/2025. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:38 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,049 | $30.73 | $93,695.77 |
DisclosureSEC source: 0001520262-26-000046 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,389 Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:38 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000046 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:46 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 7,689 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000033 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,690 Underlying: Ordinary Shares · 7,689 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:46 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,414 | $32.19 | $109,896.66 |
DisclosureSEC source: 0001520262-26-000033 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,572 Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:46 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 7,689 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000033 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:22 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 7,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · derivative · entry 6 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,019 Underlying: Ordinary Shares · 7,673 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:22 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,407 | $32.00 | $109,024.00 |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · nonDerivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,297 Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:22 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 7,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:22 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,897 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:22 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,504 | $32.02 | $112,198.08 |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,031 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:22 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000026 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:11 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 7,454 | $33.55 | $250,081.70 |
DisclosureSEC source: 0001520262-26-000016 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,638 Read SEC document |
| February 05, 2026 Filed Feb 7, 2026 00:11 UTC | Alkermes plc. ALKS · Entity 2392 | GrantOrdinary Shares | 25,352 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000016 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,092 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 23, 2023 with a three-year performance period that ended on December 31, 2025 (the "2023 PRSUs"). The vesting of this portion of the 2023 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a relative total shareholder return modifier and represents the final vesting event under the 2023 PRSUs. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-26-000009 · form4.xml · derivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,356 Underlying: Ordinary Shares · 5,000 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:52 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 4,000 | $33.54 | $134,160.00 |
DisclosureSEC source: 0001520262-26-000009 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,740 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:52 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 5,000 | $34.24 | $171,224.50 |
DisclosureSEC source: 0001520262-26-000009 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,740 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.67 to $34.64. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $19.34 | $96,700.00 |
DisclosureSEC source: 0001520262-26-000009 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:23 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-26-000004 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,356 Underlying: Ordinary Shares · 5,000 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:23 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 5,000 | $30.00 | $150,005.00 |
DisclosureSEC source: 0001520262-26-000004 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,740 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:23 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $19.34 | $96,700.00 |
DisclosureSEC source: 0001520262-26-000004 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 21:39 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 4,000 | $28.00 | $112,000.00 |
DisclosureSEC source: 0001520262-26-000002 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,740 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:21 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,748 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-25-000014 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,356 Underlying: Ordinary Shares · 3,748 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:21 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 3,748 | $30.00 | $112,447.12 |
DisclosureSEC source: 0001520262-25-000014 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,740 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.03. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.